Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP6590 in Participants With Normal Weight, Overweight and Obesity
NCT07721597Phase 1Recruiting
- Sponsor
- Zealand Pharma
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing ZP6590 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at 17 weeks. Started Jul 2026; status: recruiting.
02
Drugs
ZP6590
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07721597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721597.